Top Markets
Coin of the day
Allergy Therapeutics plc Allergy Therapeutics plc

Allergy Therapeutics plc

AGY
Classifica tra le azioni #35053
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and... Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside diagnostic tools and prescription solutions for pollen-related allergies, including those caused by grasses, weeds, and trees. Its diverse product portfolio features Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. Furthermore, Allergy Therapeutics is actively advancing new vaccine candidates designed to address sensitivities to trees, grass, house dust mites, animal dander, and peanuts. With operations spanning Central Europe, Southern Europe, the United Kingdom, and various other international markets, Allergy Therapeutics plc was established in 2004 and is headquartered in Worthing, UK.
Prezzo delle azioni
$0.07143683
Ultima sincronizzazione: 2026-08-14
Capitalizzazione di mercato
$4.52M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-37.27%
Paese
GB
Scambia Allergy Therapeutics plc (AGY)

Categoria

Rapporto P/B per Allergy Therapeutics plc (AGY)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Allergy Therapeutics plc, il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Allergy Therapeutics plc da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti